Norgine

vorige Seite Seite 1 von 7 nächste Seite

Norgine B.V. enters into exclusive distribution agreement for the commercialisation of PLENVU® in China with Beijing Podconley Pharmaceutical Technology & Development Co., Ltd.

NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. (Beijing Podconley), today announced an exclusive …

OTE0003
16.06.2021 10:00
 

Norgine B.V. Announces New European Healthcare Subsidiary To Strengthen Its Consumer Healthcare Portfolio

Norgine B.V. ("Norgine"), today announced the establishment of a wholly-owned subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which will be dedicated to consumer healthcare.

OTE0002
01.12.2020 09:00
 

Norgine B.V. Completes Important Regulatory Milestone For Angusta® (Misoprostol) In Europe For Oral Induction Of Labour

- Norgine will now seek to extend ANGUSTA®'s licence to a number of European countries

OTE0003
17.08.2020 11:01
 

Norgine B.V. Senior Management Changes: Christopher Bath Appointed Chief Operating Officer

Norgine B.V. (Norgine) today announced that Christopher Bath has been appointed Chief Operating Officer (COO) effective 1st July 2020.

OTE0007
16.06.2020 11:01
 

Norgine B.V. Acquires Azanta A

S, Strengthening Its Position as a Leading European Specialist Pharmaceutical Company

OTE0004
24.03.2020 16:55
 

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe

Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today announced a number of deals for the commercialisation of Norgine's product PLENVU® around the world.

OTE0002
12.02.2020 10:01
 

SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware

SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai …

OTE0003
09.09.2019 09:01
 

New Study Shows Rifaximin Significantly Reduced the Number and Length of Hospitalisations in Patients With Overt Hepatic Encephalopathy (HE) Awaiting Liver Transplatation

* Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver transplantation

OTE0001
11.06.2019 10:02
 

Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]

* FERACCRU ® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel …

OTE0002
04.03.2019 13:09
 

Neue Daten von Norgine offenbaren Diskrepanz zwischen Patientenerwartung und klinischer Praxis hinsichtlich der Darmvorbereitung für Darmspiegelungen[1]

* Fast neun von zehn Patienten erwarten, dass sie max. 2 Liter Flüssigkeit zur Darmvorbereitung trinken müssen

OTS0064
22.10.2018 11:01
 

Norgine wird Daten für Plenvu® und Xifaxan® bei United European Gastroenterology Week vorstellen

* Drei Poster mit Bezug auf XIFAXAN® - zwei der Poster werden als Poster of Excellence im Rahmen von Poster Champ-Sessions vorgestellt

OTS0007
19.10.2018 08:02
 
vorige Seite nächste Seite